...
首页> 外文期刊>British Journal of Cancer >Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy
【24h】

Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy

机译:口服与静脉注射5-氨基戊酸进行光动力治疗

获取原文

摘要

Endogenously synthesised protoporphyrin IX (PpIX) following the administration of 5-amino-laevulinic acid (ALA) is an effective photosensitiser for photodynamic therapy (PDT). Following intravenous administration, PpIX accumulates predominantly in mucosa of hollow viscera and on light exposure, mucosal ablation results with relative sparing of the submucosa and muscularis layers. Oral administration is effective with ALA in contrast to conventional exogenous photosensitisers such as haematoporphyrin derivative and phthalocyanines. Oral administration of ALA is also simpler, safer, cheaper and more acceptable to patients. We studied the porphyrin sensitisation kinetics profile in the stomach, colon and bladder in normal rats following enterally and parenterally administered ALA using microscopic fluorescence photometric studies of frozen tissue sections. Mucosal cells in all three organs exhibit higher fluorescence levels as compared with underlying smooth muscle following both intravenous and oral administration. Peak concentration were seen 4 h after sensitisation at the highest doses used (200 mg kg-1 i.v., 400 mg kg-1 oral), and slightly earlier with lower doses. The temporal kinetics of both routes of administration were similar although a higher oral dose was required to achieve the same tissue concentration of PpIX. The highest level of fluorescence was achieved in the gastric mucosa and in decreasing levels, colonic and bladder mucosa. A similar degree of mucosal selectivity was achieved in each organ with each route of administration but an oral dose in excess of 40 mg kg-1 was required to achieve measurable PpIX sensitisation. In a pilot clinical study, two patients with inoperable rectal adenocarcinomas were given 30 mg kg-1 and one patient with sigmoid colon carcinoma was given 60 mg kg-1 ALA orally. Serial biopsies of normal and tumour areas were taken over the subsequent 24 h. Fluorescence microscopy of these specimens showed maximum accumulation of PpIX 4 to 6 h after administration of 30 mg kg-1 ALA. There was greater PpIX accumulation in tumour than adjacent normal mucosa in two patients. Preferential PpIX accumulation in tumour was greater in the patient receiving 60 mg kg-1 ALA.
机译:内源合成的原卟啉IX(PpIX)在使用5-氨基-花生油酸(ALA)后是用于光动力疗法(PDT)的有效光敏剂。静脉内给药后,PpIX主要聚集在空心内脏的粘膜中,并且在光线照射下,粘膜消融导致粘膜下层和肌层相对较少。与常规的外源性光敏剂(如血卟啉衍生物和酞菁类)相比,口服ALA有效。口服ALA也更简单,更安全,更便宜并且更容易为患者接受。我们使用冷冻组织切片的显微荧光光度法研究了肠内和肠胃外施用ALA后正常大鼠胃,结肠和膀胱中卟啉的敏化动力学曲线。与静脉内和口服给药后的基础平滑肌相比,所有三个器官的粘膜细胞均显示出更高的荧光水平。致敏后4小时,在最高剂量下(口服200 mg kg-1,口服400 mg kg-1)观察到峰值浓度,在较低剂量下则达到峰值。两种给药途径的时间动力学相似,尽管需要更高的口服剂量才能达到相同的PpIX组织浓度。在胃粘膜中达到最高水平的荧光,在结肠和膀胱粘膜中降低水平。在每种给药方式下,每个器官的黏膜选择性达到相似的程度,但是需要超过40 mg kg-1的口服剂量才能达到可测量的PpIX致敏性。在一项临床试验研究中,对两名患有无法手术的直肠腺癌的患者口服30 mg kg-1,对一名乙状结肠癌的患者口服60 mg kg-1 ALA。在随后的24小时内对正常和肿瘤区域进行连续活检。这些标本的荧光显微镜检查显示,在施用30 mg kg-1 ALA后4至6 h,PpIX的最大积累。在两名患者中,肿瘤中PpIX的积聚比邻近的正常黏膜大。接受60 mg kg-1 ALA的患者在肿瘤中优先积累PpIX。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号